1351580-15-8 Usage
Uses
Used in Pharmaceutical Industry:
(R)-1-(2,3-Difluorophenyl)ethanaMine hydrochloride is employed as an antidepressant medication for the treatment of depression. It is used to increase serotonin levels in the brain, which helps in improving mood, appetite, and energy levels.
Used in Treatment of Mental Health Disorders:
In addition to its antidepressant properties, (R)-1-(2,3-Difluorophenyl)ethanaMine hydrochloride is used as a therapeutic agent for the treatment of various mental health disorders, including obsessive-compulsive disorder, panic disorder, and bulimia nervosa. Its effectiveness in these conditions is attributed to its ability to regulate serotonin levels in the brain.
Used in Medication Formulation:
(R)-1-(2,3-Difluorophenyl)ethanaMine hydrochloride is used as an active pharmaceutical ingredient in both generic and brand name formulations. It is typically administered orally, making it a convenient and accessible treatment option for patients suffering from depression and other related mental health conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1351580-15-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,1,5,8 and 0 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1351580-15:
(9*1)+(8*3)+(7*5)+(6*1)+(5*5)+(4*8)+(3*0)+(2*1)+(1*5)=138
138 % 10 = 8
So 1351580-15-8 is a valid CAS Registry Number.
1351580-15-8Relevant articles and documents
3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
-
Page/Page column 158; 159, (2014/09/29)
The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
-
Paragraph 0501; 0504, (2014/09/03)
The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.